Tirzepatide: The Weight Loss Drug with Potential Cardiovascular Benefits
A recent study has shed light on the potential cardiovascular benefits of the weight loss and diabetes drug, tirzepatide, which is also known under the brand names Mounjaro and Zepbound. The study found that overweight and obese patients taking tirzepatide experienced significant reductions in their blood pressure. This impressive finding suggests an additional benefit of the drug beyond its initial approval uses, which include type 2 diabetes mitigation and weight loss. Interestingly, the study also highlights the potential impact of tirzepatide on cardiovascular events, suggesting a need for further research in this area.
The Impact of Tirzepatide on Blood Pressure
According to sources, the new weight loss medication tirzepatide significantly lowers systolic blood pressure in adults with obesity. The medication works by mimicking two metabolic hormones in the body and has been approved for treating Type 2 diabetes and chronic weight management for people with obesity. The reduction in blood pressure was consistent across different subgroups of participants in the study. Furthermore, the medication was found to be effective at improving cardiometabolic complications of obesity including hypertension, Type 2 diabetes, and dyslipidemia.
A Closer Look at the Study
Participants in the study who took tirzepatide had significantly lower blood pressures after 36 weeks of using the medication. Notably, participants taking the drug had systolic blood pressures that were 7.4 to 10.0 millimeters of mercury lower than those of participants taking a placebo. These reductions in blood pressure are comparable to what would be expected with a full dose of a blood pressure medicine, making tirzepatide a potentially useful tool for individuals trying to control their blood pressure and reduce their risk of heart attack and stroke.
Details of the SURMOUNT 1 Trial
The Phase 3 SURMOUNT 1 trial, which assessed the effects of tirzepatide on weight loss, enrolled 2539 patients with a BMI of 30 kg/m2 or greater. The results suggested significant weight loss with tirzepatide compared to a placebo, leading to the FDA’s approval of tirzepatide for use in chronic weight management. A substudy of the trial included 600 patients and found that changes in ambulatory systolic blood pressure were partially mediated by weight changes, with tirzepatide also resulting in an increase in heart rate.
Moving Forward with Tirzepatide
Despite the promising results, further studies are needed to determine the long-term impact of tirzepatide on cardiovascular events and the effects of discontinuing the medication. However, the initial data are encouraging, indicating the effectiveness of novel weight loss medications in reducing body weight and improving cardiometabolic complications of obesity.
It’s also important to note that the list price of Mounjaro and other weight loss drugs has reportedly increased. The drug has generated $3 billion in global revenue for Eli Lilly, highlighting its significant impact on the market. As research continues, the potential cardiovascular benefits of tirzepatide could further solidify its position as a leading medication in the fight against obesity and related health issues.